



# HHS Public Access

Author manuscript

Nature. Author manuscript; available in PMC 2015 March 25.

Published in final edited form as:

Nature. 2014 September 25; 513(7519): 555–558. doi:10.1038/nature13575.

## Antifungal drug resistance evoked via RNAi-dependent epimutations

Silvia Calo<sup>1</sup>, Cecelia Shertz-Wall<sup>1</sup>, Soo Chan Lee<sup>1</sup>, Robert J. Bastidas<sup>1</sup>, Francisco E. Nicolás<sup>5,6</sup>, Joshua A. Granek<sup>1,2,3</sup>, Piotr Mieczkowski<sup>4</sup>, Santiago Torres-Martinez<sup>6</sup>, Rosa M. Ruiz-Vazquez<sup>6</sup>, Maria E. Cardenas<sup>1</sup>, and Joseph Heitman<sup>1,\*</sup>

<sup>1</sup>Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710

<sup>2</sup>Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710

<sup>3</sup>Bioinformatics Group, Duke Center for the Genomics of Microbial Systems, Duke University Medical Center, Durham, North Carolina 27710

<sup>4</sup>High-Throughput Sequencing Facility, University of North Carolina, Chapel Hill, North Carolina 27599

<sup>5</sup>Regional Campus of International Excellence “Campus Mare Nostrum”, Murcia 30100, Spain

<sup>6</sup>Department of Genetics and Microbiology, Faculty of Biology, University of Murcia, Murcia 30100, Spain

### Abstract

Microorganisms evolve via mechanisms spanning sexual/parasexual reproduction, mutators, aneuploidy, Hsp90, and even prions. Mechanisms that may seem detrimental can be repurposed to generate diversity. Here we show the human fungal pathogen *Mucor circinelloides* develops spontaneous resistance to the antifungal drug FK506 (tacrolimus) via two distinct mechanisms. One involves Mendelian mutations that confer stable drug resistance; the other occurs via an epigenetic RNA interference (RNAi)-mediated pathway resulting in unstable drug resistance. The peptidyl-prolyl isomerase FKBP12 interacts with FK506 forming a complex that inhibits the protein phosphatase calcineurin<sup>1</sup>. Calcineurin inhibition by FK506 blocks *M. circinelloides*

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: [http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\*Corresponding author Room 322 CARL Building, Box 3546 Research Drive, Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA, [heitm001@duke.edu](mailto:heitm001@duke.edu), Phone: (919) 684-2824, FAX: (919) 684-5458.

#### Author contributions

S.C., C.W., S.T.-M., R.M.R.-V., M.E.C., and J.H. designed experiments, interpreted data, and wrote the paper. S.C., C.W., R.J.B., S.C.L., and F.E.N. performed experiments. P.M. sequenced the sRNA library. J.A.G. analyzed deep-sequencing data. S.T.-M., R.M.R.-V., M.E.C. and J.H. provided materials.

**Supplementary Information** is available in the online version of the paper at [www.nature.com/nature](http://www.nature.com/nature).

The authors declare no competing financial interests.

Sequences for the *fkbA* gene from WT strain NRRL3631 and epimutant strains (EM1, EM2, EM3) were deposited in GeneBank with accession numbers KF203228, KF203229, KF203230, and KF203231. Raw data from high-throughput sRNA sequencing of WT, epimutant, and revertant strains have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE56353 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56353>).

transition to hyphae and enforces yeast growth<sup>2</sup>. Mutations in the *fkbA* gene encoding FKBP12 or the calcineurin *cnbR* or *cnaA* genes confer FK506 resistance (FK506<sup>R</sup>) and restore hyphal growth. In parallel, RNAi is spontaneously triggered to silence the FKBP12 *fkbA* gene, giving rise to drug-resistant epimutants. FK506<sup>R</sup> epimutants readily reverted to the drug-sensitive wild-type (WT) phenotype when grown without drug. The establishment of these epimutants is accompanied by generation of abundant *fkbA* small RNA (sRNA) and requires the RNAi pathway as well as other factors that constrain or reverse the epimutant state. Silencing involves generation of a double-stranded RNA (dsRNA) trigger intermediate from the *fkbA* mature mRNA to produce antisense *fkbA* RNA. This study uncovers a novel epigenetic RNAi-based epimutation mechanism controlling phenotypic plasticity, with possible implications for antimicrobial drug resistance and RNAi-regulatory mechanisms in fungi and other eukaryotes.

The pathogenic fungus *M. circinelloides* grows as hyphae aerobically, and as yeast in anaerobic/high CO<sub>2</sub> conditions<sup>3</sup>. FKBP12 is a prolyl-isomerase conserved throughout eukaryotes that interacts with FK506 and rapamycin and mediates their antifungal activity in *M. circinelloides*<sup>4</sup> and other fungi. The FKBP12-FK506 and FKBP12-rapamycin complexes inhibit the protein phosphatase calcineurin and the Torkinase, respectively<sup>1,5</sup>. FK506 inhibition of calcineurin blocks hyphal growth of *M. circinelloides* and enforces yeast phase growth<sup>2</sup> (Fig. 1a, Extended Data Fig. 1a). Exposure to FK506 yields at moderate frequency ( $\sim 1 \times 10^{-6}$ ) drug-resistant isolates exhibiting hyphal growth emerging from the yeast colony periphery (Extended Data Fig. 1a). A subset of FK506<sup>R</sup> isolates harbor mutations in the *fkbA* gene encoding FKBP12 or the calcineurin A or B subunit genes *cnaA* and *cnbR* (45/64 isolates [ $\sim 70\%$ ], Supplementary Table 1)<sup>2</sup>.

However, several FK506<sup>R</sup> isolates (17/64,  $\sim 27\%$ ) harbored no mutations in the *fkbA* or calcineurin target genes. These isolates exhibited resistance to FK506 and rapamycin, but not to cyclosporin A (which similar to FK506 enforces largely yeast growth, Fig. 1a) or other drugs (nystatin, amphotericin B, not shown), arguing against multidrug resistance mechanisms. These unusual drug-resistant isolates also reverted frequently within several generations of vegetative growth on drug-free media and were restored to a WT phenotype (yeast growth on FK506) (Extended Data Figure 1b, Extended Data Fig. 1c). Expression analyses revealed a complete loss of *fkbA* mRNA and FKBP12 protein in these drug-resistant isolates when grown in media containing FK506. In contrast, mRNA and protein levels were reduced but detectable in some resistant isolates (R) when grown in drug-free media (Fig. 1b-c), and were restored to WT levels in revertant isolates that became FK506-sensitive (FK506<sup>S</sup>) (S) following passage in drug-free media (Fig. 1b-c).

Because drug resistance was reversible and an active RNAi pathway is present in the organism<sup>6,7</sup> we entertained the hypothesis that drug resistance is RNAi-mediated. Remarkably, sRNAs complementary to *fkbA* were detected in these unusual drug-resistant isolates (Fig. 2a, Extended Data Fig. 2a), suggesting a new role for RNAi in development of transient resistance to antifungal drug exposure. Consistent with the expression analyses, the sRNA signal was highly abundant during growth with FK506 (100%), less abundant when the isolates were grown in drug-free media ( $\sim 62$  and  $25\%$  for EM2 and EM3 respectively, Fig. 2a), and lost when drug resistance reverted (0-0.02%). The *fkbA* silencing was not

associated with DNA methylation in *M. circinelloides* (Extended Data Fig. 2b). We term these unusual drug-resistant isolates epimutants, by analogy with studies in fungi<sup>8,9</sup>, plants<sup>10</sup>, and animals<sup>11-13</sup>, in which epimutations have been described as silencing of genes that are usually active or vice versa<sup>11</sup>.

Our first hypothesis was that RNAi could be triggered via dsRNA production from the overlap in the 3' regions between *fkba* and its convergently transcribed neighboring gene *patA* (Extended Data Fig. 3 and Supplementary Table 2). But *patA* mutants did not show any effect on the frequency of *fkba* epimutational silencing (Table 1, Supplementary Table 1, Extended Data Fig. 4). 3' RACE assays confirmed the mRNA from *fkba* gene and the *pyrG* marker replacing *patA* were not overlapping (Supplementary Table 2). Thus, expression of *patA* to generate overlapping RNA molecules is not necessary for *fkba* silencing.

As *fkba* is a highly expressed gene (Fig. 1c), and a high RNA turnover rate has been implicated in production of aberrant RNA and triggering of silencing<sup>14-17</sup>, we speculated that an *fkba* antisense RNA may be generated by an RNA-dependent RNA polymerase (RdRP)<sup>18</sup>. Northern blot analysis with an *fkba* antisense-specific probe revealed an antisense *fkba* mRNA in all strains with robust *fkba* expression (Fig. 1c). This *fkba* antisense RNA is perfectly complementary to the intron spliced mature *fkba* sense mRNA, and is 5' capped and poly-adenylated (Extended Data Fig. 5). Thus, the antisense RNA is generated from the mature *fkba* mRNA. The *fkba* antisense RNA is expressed in the WT strain (Fig. 1c), however RNAi is activated in only a subset of cells selected with FK506. The *in vivo* efficiency of dsRNA formation or its transport to the cytoplasm may limit sRNA levels restricting silencing to fewer cells. Only traces of antisense sRNA complementary to *fkba* (16 reads per million) were detected in the WT strain by high-throughput sequencing (Extended Data Fig. 6), supporting this hypothesis.

To test if mutations may have occurred to promote the formation of epimutations, the reverted and now sensitive epimutant strains were exposed to a second round of FK506 to isolate mutants/epimutants. The frequency of epimutation versus mutation to FK506<sup>R</sup> in the reverted epimutant strains was similar or even lower than in the parental WT strain (Extended Data Fig. 7). Thus, the underlying mechanism appears solely epigenetic and does not require any genetic change in the genome to promote epimutation.

High-throughput sequencing demonstrated abundant sRNAs complementary to the *fkba* mRNA (antisense) as well as sense sRNA in three epimutant resistant isolates, but these were barely detectable in the WT strain or in the two corresponding FK506<sup>S</sup> revertants analyzed (Fig. 2b). Some sRNA sequences spanned exon-exon junctions (Fig. 2b, Extended Data Fig. 8a), indicating that the source and target of the sRNA is mature mRNA. Most of these sRNAs average 21-24 nt, with a bias towards 5' terminal uridine (Fig. 2c), features typical of sRNA that interact with Argonaute. No further loci were detected exhibiting the same pattern of sRNA production: high level in epimutants, and very low levels in WT and reverted strains (Extended Data Fig. 8b). Silencing pathways can operate constitutively on *M. circinelloides* endogenous genes during normal growth<sup>7</sup>. In contrast, the FK506-selected silencing of the *fkba* gene may not affect other loci. However, no other phenotypes were

selected and sRNAs are often lost without selection (Fig. 2a, Extended Data Figs. 1b and 8b).

To test if silencing was driven and enhanced by a genome-wide increase in stress-activated RNAi, the WT strain was exposed to stress conditions prior to FK506 exposure (Supplementary Table 3). However, analysis of recovered FK506<sup>R</sup> isolates did not show an increase (or decrease) of epimutation frequency in *fkba* (Supplementary Table 4). Thus, either stress fails to activate RNAi or we have not identified the precise activating stress. The calcineurin inhibitor CsA also did not increase epimutations conferring FK506 resistance; thus inhibition of calcineurin (by CsA or FK506) does not activate RNAi.

To investigate if sRNAs generated against *fkba* are produced by canonical RNA silencing, we screened for epimutants in mutants lacking RNAi pathway components. No epimutants were found in *dcl2*, *ago1*, or *rdrp2* mutants (Table 1, Extended Data Fig. 9a), showing that Dcl2 (Dicer), Ago1 (Argonaute), and RdRP2 are necessary for endogenous silencing of *fkba*. Dcl2 and Ago1 are essential for both transgene-induced and endogenous silencing in *M. circinelloides*<sup>7,19,20</sup>. RdRP2 is essential to amplify RNAi signals for transgene-induced silencing<sup>18</sup>, but was thought to play a role secondary to RdRP1 for endogenous RNAi silencing<sup>7</sup>. Instead, we find RdRP2 is crucial, suggesting different pathways for endogenous silencing operate in *M. circinelloides*, which may be correlated with the four different known classes of sRNAs<sup>7</sup>. Surprisingly, we found only one epimutant in two independent *dcl1* mutants (1/46 FK506<sup>R</sup> isolates, 2.2%, Table 1, Supplementary Table 1 and Extended Data Fig. 9a). Dcl1 is not known to play any essential role in transgene-induced or endogenous silencing<sup>7,21</sup>, but does provide an auxiliary role in mutants lacking Dcl2<sup>19</sup>. The paucity of *fkba* epimutants in the *dcl2* and *dcl1* mutant backgrounds suggests that both Dcl1 and Dcl2 are involved in epimutational *fkba* silencing. *ago2* and *ago3* mutants exhibited a WT frequency of silencing (15-17%, Table 1, Extended Data Figs. 9a and 2a), thus Ago2 and Ago3 are dispensable for epimutation<sup>20</sup>. These results reveal establishment of epimutants in *M. circinelloides* depends upon Dcl2, Dcl1, Ago1, and RdRP2. Except for Dcl1, these genes are involved in biogenesis of the known class I type of sRNAs<sup>7</sup>. Thus, although epimutant genetic requirements could suggest a distinct sRNA class is involved (given the role of Dcl1), we cannot exclude that *fkba* silencing is due to an atypical class I sRNA.

Unexpectedly, our studies revealed a novel role for RdRP1 in constraining epimutational silencing. RdRP1 is required for RNA silencing of exogenous sense transgenes in *M. circinelloides*. When DNA alleles producing dsRNA are introduced, this bypasses RdRP1 to evoke gene silencing<sup>18</sup>. As noted above, RdRP1 has a major role in endogenous silencing<sup>7</sup>. RdRP1 is hypothesized to be central for activating RNAi by generating dsRNA from the single-stranded RNA (ssRNA) precursor, both from sense transgenes or mRNA. In this model RdRP1 should be essential for triggering *fkba* silencing because it involves an *fkba* dsRNA (Fig. 1c, Extended Data Fig. 5). Surprisingly, the *rdrp1* mutant showed an elevated silencing rate of ~80% (~22% in WT, Table 1, Extended Data Figs. 9a and 2a), and the epimutants isolated in this mutant did not revert on drug free media (EM4, Extended Data Fig. 1b). In *Caenorhabditis elegans* the *rrf-3* mutant lacking one of several RdRPs has a similar enhanced RNAi phenotype<sup>22,23</sup>. RRF-3 has also been proposed to generate dsRNA

from mRNA templates<sup>24</sup>, hence RdRP1 and RRF-3 could serve analogous roles. Furthermore, the exosome and RNAi pathways in *Schizosaccharomyces pombe* compete in their degradation activities. Both mechanisms share common targets<sup>25</sup> and in the *rdrp1* mutant sRNA formation is abolished, and mRNAs are primarily directed to the exosome<sup>26</sup>. In *Mucor*, RdRP1 could have an opposing role to RNAi, promoting assembly of exosome machinery on specific mRNA targets and thereby avoiding activation of RNAi under normal conditions, as was suggested previously<sup>7</sup>.

To test which RdRP might generate dsRNA from *fkba* mRNA, we tested for *fkba* antisense RNA in silencing mutants (Extended Data Fig. 9b). All strains analyzed expressed the antisense RNA at similar levels, even in the *rdrp1* and *rdrp2* mutants. The two RdRP polymerases could play a redundant role in generating *fkba* antisense RNA (*rdrp1 rdrp2* double mutants appear inviable, precluding analysis, not shown), or other *rdrp* genes may participate.

Together these results provide evidence for a different route processing endogenous sRNA, wherein RdRP2, Ago1, and both Dcl proteins are necessary to silence mRNA expression via epimutation, and RdRP1 plays an unexpected role constraining epimutational silencing. We consider two possible models. In the first, sRNAs are produced constitutively and stochastically at low levels against the entire genome or some designated loci, allowing adaptation to environments through an RNAi-based pathway. In the second model, some mechanism activates RNAi under adverse/novel physiological conditions, facilitating genomic and phenotypic plasticity. Either could explain the broad range of environments in which *M. circinelloides* grows, and the limited antifungal drug susceptibility.

Previous studies showed the *M. circinelloides* species complex includes three distinct subspecies: *M. circinelloides* f. *lusitanicus* (*Mcl*), *M. circinelloides* f. *circinelloides* (*Mcc*), and *M. circinelloides* f. *griseocyanus* (*Mcg*)<sup>27</sup>. Mating barriers and phylogenetic separation provide evidence these three lineages are different enough to represent distinct species. To generalize our findings, two *Mcc* strains [Mucho, 1006PhL<sup>28</sup>], and an *Mcg* strain [ATCC1207a] were tested in addition to the *Mcl* strains. Only the *Mcc* strains grew as yeast in the presence of FK506 (Extended Data Fig. 10a), enabling the recovery of FK506<sup>R</sup> isolates. The two exhibited different patterns of genomic plasticity; 2.5-fold more FK506<sup>R</sup> isolates were recovered from 1006PhL than from Mucho (Supplementary Table 5), and appeared earlier (5-7 days for 1006PhL, 5-15 days for Mucho). Epimutants silencing *fkba* occurred in the pathogenic isolate 1006PhL at a surprisingly more elevated rate (90%) than in Mucho (<7.7%) or the *Mcl* strains (~20-30%) (Supplementary Table 5 and Extended Data Fig. 10b). *Mcc* is the most common *Mucor* species associated with human infection. The enhanced ability to activate RNAi exhibited by the 1006PhL virulent isolate suggests RNAi may enable this fungal pathogen to readily adapt both in nature and the host. Further studies are required to elucidate whether our observations are generally applicable, or if not, how specificity is brought about.

This study underscores the ability of *M. circinelloides* to adapt to the environment through two different routes of phenotypic variation, one stable (mutation) and one transient (epimutation). This plasticity evokes a broader phenotypic repertoire including the ability to

reverse epimutations when selective pressures are relaxed. This is the first known example of epimutations involving an endogenous gene in fungi identified in a standard genetic screen, however given the ubiquity of RNAi it is unlikely to be unique. While this example involves resistance to an antifungal drug in a human fungal pathogen, these findings could have implications beyond novel modes of transient antimicrobial resistance for the broader evolutionary trajectory of this and other eukaryotes with active RNAi pathways.

## METHODS

### Strains and growth conditions

The *leuA* leucine auxotrophic strain R7B, derived from *M. circinelloides f. lusitanicus* CBS277.49 (syn. *Mucor racemosus* ATCC1216b), was used as the WT strain to compare with the *pata* and silencing mutant strains, as they were generated in the R7B background<sup>18-21</sup>. The strains were grown at room temperature (~26°C) on yeast extract peptone dextrose agar (YPD, 10 g/L yeast extract, 20 g/L 4 peptone, 20 g/L dextrose, 2% agar), MMC medium pH=4.5 (1% casamino acids, 0.05% yeast nitrogen base without amino acids and ammonium sulfate, 2% glucose), or YNB minimal medium<sup>29</sup> pH 4.5, supplemented with 1 µg/mL of FK506 (Prograf), 100 ng/mL of rapamycin, or 100 µg/mL of CsA when needed. The cultures were routinely incubated for 48hr except when noted otherwise or for the isolation of FK506-resistance patches, when the cultures were incubated for as long as 4 weeks in some cases. The media to test the different stress conditions was prepared by adding the specific compounds at the concentrations indicated (see Supplementary Table 3) except for trisporic acid, which was sprayed over the spores (approximately 100 µg of trisporoid as suggested by previous studies<sup>30</sup>). All of the compounds were added to YPD medium unless otherwise specified.

### FK506 resistant strains isolation

FK506<sup>R</sup> isolates were obtained after growing the different strains on YPD containing 1 µg/mL of FK506 for three days to three-four weeks at room temperature, until patches with hyphal growth were observed. Each isolate was derived from an independent subculture grown on a different petri dish. The isolates were analyzed after at least three generations of vegetative growth in the presence of FK506 to ensure a high proportion of the nuclei in the mycelium syncytium were mutant or silenced.

### DNA/RNA extraction and analysis

The isolates were grown on MMC media pH=4.5, supplemented with 1 µg/mL of FK506 when necessary, prior to DNA or RNA purification. The FKBP12 gene *fkbA* and calcineurin genes *cnaA*, *cnaB*, *cnaC*, and *cnbR* were sequenced from DNA purified with CTAB and chloroform extraction from lyophilized mycelia. The FK506-resistant isolates obtained in a mutant background were verified by junction PCR for the deletion of the proper gene. Small and total RNAs were extracted using Trizol as described previously<sup>6</sup> from frozen mycelia in liquid nitrogen. 25-35 µg of sRNAs were separated by electrophoresis on 15% TBE-Urea gels (Invitrogen), electrotransferred to Hybond N+ filters at 400 mA for 1 hour in 0.5X TBE, and cross-linked by irradiation with ultraviolet irradiation (2x 1.2 Q 105 mJ/cm<sup>2</sup>). Prehybridization and hybridization were carried out with ultrasensitive hybridization buffer

UltraHyb (Ambion). The *fkbA* antisense-specific and 5S *rRNA* riboprobes were prepared by in vitro transcription using the Maxiscript transcription kit (Ambion) following supplier-recommended protocols. Riboprobes were treated as described previously<sup>6</sup> to result in an average size of 50 nt.

### Protein cell extracts and analysis

Whole proteincell extracts were prepared from mycelia grown on MMC media pH=4.5 and frozen in liquid nitrogen as described previously<sup>31</sup> with some modifications. The sample was ground to a powder with a mortar and pestle and transferred to TSA extraction buffer (10 mM Tris-HCl pH=8.0 and 0.15 M NaCl) with protease inhibitors (complete Mini from Roche), and 1 mM of Benzamidine. After 30 minutes incubation on ice and 30 minutes centrifugation at top speed at 4°C, the amount of protein in the supernatant was quantified by Bradford assay (BioRad). Protein (100-120 µg) was loaded in 4-20% polyacrylamide gels for western blot analysis. Antiserum against ScFKBP12 raised in rabbits<sup>32</sup> was used to detect FKBP12 in *Mucor*, and this sera was previously shown to be cross-reactive<sup>4</sup>. Mouse monoclonal antibodies against  $\alpha$ -Tubulin (Sigma, T5168) served as the loading control.

### Disruption of *patA*

A disruption allele containing the *pyrG* gene as a selectable marker flanked by sequences 5' and 3' of the *patA* ORF was generated via overlap PCR and used to generate *patA* null mutants by gene replacement. Primers used for the construction of the disruption allele and the confirmation of the deletion are listed in Supplementary Table 6. Strain MU402 (*leuA*-, *pyrG*-) was transformed with the *patA* : *pyrG* disruption cassette as described previously<sup>33</sup> by electroporation of protoplasts obtained from spores after treatment with chitosanase and lysing enzymes. 5' and 3' junction PCRs were used to identify transformants in which homologous replacement of the *patA* locus had occurred and confirmed with both spanning and ORF specific PCR analysis.

### 3' and 5' RACE assays

Total RNA for 3' and 5' RACE assays was extracted following the protocol for filamentous fungi supplied with the RN easy Plant Mini Kit (QIAGEN). The First Choice RLM-RACE kit (Ambion) was utilized for 3' and 5' UTR amplification and the gene-specific primers used are listed in Supplementary Table 6. Sequences were aligned with Serial-Cloner software.

### High-throughput sRNA sequencing

sRNA libraries were prepared following the instructions of the TruSeq Small RNA Sample Prep Kit (Illumina). sRNA-enriched samples extracted with the mirVana miRNA isolation kit (Ambion) as previously described<sup>7</sup> were size-fractionated by electrophoresis and the 18-24 nt fraction purified from the gel was used as input. The library was sequenced by the High-Throughput Sequencing Facility (HTSF), UNC Chapel Hill, using the Illumina platform (HiSeq 2000).

Raw sRNA sequences were processed using fastx\_clipper <[http://hannonlab.cshl.edu/fastx\\_toolkit/](http://hannonlab.cshl.edu/fastx_toolkit/)> to remove adapter sequences. The adapter sequences trimmed from each

sample are listed in Supplementary Table 7. Because samples were multiplexed for sequencing, each sample was trimmed using a multiplex index specific sequence. The adapter sequences that were trimmed are based on those supplied by the manufacturer (Oligonucleotide sequences © 2007-2011 Illumina, Inc. All rights reserved). Trimmed reads were then mapped to the *Mucor circinelloides* CBS277.49 v2.0 genome<sup>34</sup> using TopHat<sup>35</sup> (TopHat version 2.0.5, Bowtie version 2.0.0.7, Samtools version 0.1.18.0) and the basic library data is represented in Supplementary Table 8. The downloaded genome annotation file was modified to include the coordinates of the 3' UTRs for the *pataA* and *fkba* genes as determined by 3' RACE (see Supplementary Table 2); this modified annotation file served as the input for TopHat.

Both parts of Figure 2c represented the antisense reads of *fkba* from the EM1-R samples, and show plus strand reads that map entirely within the *fkba* gene (1803250-1803768 on scaffold\_03). Figure 2b presents all reads that map to the *fkba* gene, and the read counts were normalized to the total number of mapped reads in the sample.

Extended Data Fig. 8a shows a map for all of the reads in the EM1-R sample, emanating from the region of the exon 1 – exon 2 boundary of the *fkba* gene (i.e. reads completely within the range 1803668-1803774 on scaffold\_03). Only reads with at least five copies in the sample are shown.

Extended Data Fig. 6 consists of the sequence logos<sup>36</sup> for all *fkba* antisense reads (plus strand in the range 1803250-1803768 on scaffold\_03) in the WT sample, at each read length observed.

Figures 2b, 2c, Extended Data Fig. 6, and 8a were generated using custom software, based on a number of existing software libraries<sup>36-41</sup>. The analysis and figures can readily be reproduced by downloading the source code from <[https://bitbucket.org/granek/mucor\\_srna](https://bitbucket.org/granek/mucor_srna)>. Raw data from the high-throughput sRNA sequencing of WT, epimutant, and revertant strains have been deposited in NCBI's Gene Expression Omnibus<sup>42</sup> and are accessible through GEO Series accession number GSE56353 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56353>).

To search for genes with sRNA patterns correlated with *fkba* (Extended Data Fig. 8b), antisense read counts were determined for each annotated gene using htseq-count<sup>43</sup>, counts were normalized using the R package DESeq2<sup>38</sup>, and genes with counts so low (mean normalized count across samples less than 10) that any true differences between samples are confounded by Poisson noise were excluded from consideration. The similarity to *fkba* was determined by computing the Kendall rank correlation coefficient for each annotated gene in the genome. The fifty genes with the highest correlation coefficient (i.e. most closely correlated with *fkba*) were plotted using R<sup>44</sup> for comparison to *fkba*.

### GeneBank accession numbers

Sequences for the *fkba* and calcineurin genes from the WT strain NRRL3631 and the epimutant strains (EM1, EM2, and EM3) were deposited in GenBank with accession numbers WT *fkba*: KF203228, EM1 *fkba*: KF203229, EM2 *fkba*: KF203230, EM3 *fkba*:




KF203231, WT *cnaA*: KJ668831, WT *cnaB*: KJ668832, WT *cnaC*: KJ668833, WT *cnbR*: KJ668834, EM1 *cnaA*: KJ668835, EM1 *cnaB*: KJ668836, EM1 *cnaC*: KJ668837, EM1 *cnbR*: KJ668838, EM2 *cnaA*: KJ668839, EM2 *cnaB*: KJ668840, EM2 *cnaC*: KJ668841, EM2 *cnbR*: KJ668842, EM3 *cnaA*: KJ668843, EM3 *cnaB*: KJ668844, EM3 *cnaC*: KJ668845, and EM3 *cnbR*: KJ668846.

### p-value calculation

p-values listed in Table 1 are based on a Fisher Exact Probability Test for a 2×2 Contingency Table, comparing each of the *patA* and silencing mutant strains individually versus the R7B WT strain, from which all of the mutants were generated.


### Extended Data



**Extended Data Figure 1. *M. circinelloides* can develop resistance to FK506 by two mechanisms, one stable (mutations) and one transient (epimutations)**

**a**, The WT strain (NRRL3631) grows as hyphae (white, upper left panel) on YPD and as a yeast (yellow, upper center panel) on YPD containing 1 μg/mL of FK506. An FK506-


resistant patch that emerged from the southeastern edge of the yeast patch is shown after 10 days of incubation (arrow, upper right panel). Microscopic images corresponding to the culture plates at the top were taken at different incubation periods as indicated and are shown in the lower panels. For yeast growth, cells from the colony were dispersed in water on a microscope slide. The black patch (arrow) in the microscopic image in the lower right panel corresponds to the edge of the compact yeast colony. Images are representative of all of the FK506 resistant isolates obtained (see Supplementary Tables 1, 3, and 5) **b**, Epimutant strains revert during passage on drug-free media. Y=yeast, H=hyphal. Shaded areas indicate reversion of epimutants to the WT phenotype (yeast growth on YPD supplemented with 1  $\mu\text{g}/\text{mL}$  FK506). SM2 strain<sup>4</sup> harbors an A-to-G substitution (A316G) in the acceptor splice site of intron 2. Darker vertical bars indicate intervals in which some passages are not depicted. **c**, Reverted epimutant strains from (b) lost their resistance to FK506 and rapamycin (central panels) and remained sensitive to CsA whose mechanism of action does not involve FKBP12 (right panel). The images were taken after 48 hours of incubation at room temperature ( $\sim 26^\circ\text{C}$ ) on YPD or YPD media supplemented with the different drugs. Images are representative of two independent experiments. EM1-S, EM2-S, EM3-S=Epimutants 1, 2, and 3 reverted to restore FK506-sensitivity. fkbA =fkbA null mutant.



**Extended Data Figure 2. Epimutations are generated by the RNAi pathway, and are not associated with DNA methylation in *M. circinelloides***


**a.** Confirmation of the presence of sRNAs in all of the remaining epimutant isolates from the different strains lacking mutations in the *fkbA* and calcineurin genes (*cnaA*, *cnaB*, *cnaC*, and *cnbR*) not shown in Figure 2a or Extended Data Fig. 9. The numbers of the isolates correspond to those in Supplementary Table 1. sRNA blots were hybridized with an antisense-specific probe to detect *fkbA* sRNA. 5S rRNA served as a loading control. Abundant sRNAs were detected in all of the strains with the exception of three of the isolates (NRRL3631 isolate 9, R7B isolate 8, and MU410 isolate 26). These isolates also do not show any mutations in the genes analyzed (*fkbA*, *cnaA*, *cnaB*, *cnaC*, *cnbR*) and the mechanism by which they have developed FK506-resistance remains to be established. The image of the blot in which these three isolates were included is representative of two independent experiments. All of the other blots were generated only once, because a positive signal indicates the presence of sRNA. **b.** Genomic DNA (~40 µg) from the WT strain (NRRL3631), the three epimutants (1=EM1, 2=EM2, and 3=EM3), and the three reverted strains (1-S=EM1-S, 2-S=EM2-S, and 3-S=EM3-S) was treated with the methylated-DNA-

specific restriction enzyme McrBC (NEB) with or without previous treatment with the CpG methyltransferase SsI (NEB), following the manufacturer’s protocols. PCR amplification of the *fkba* locus (~1.6 kb = 732 bp 5’ upstream *fkba*, 457 bp *fkba* ORF and 435 bp 3’ downstream *fkba*) was carried out using 100 ng of purified DNA. PCR amplification after McrBC treatment yielded similar levels of product as the untreated samples. Virtually no product was obtained by PCR amplification in any of the samples after treatment with the CpG methyltransferase SsI followed by McrBC treatment, indicating that McrBC digested the newly methylated DNA, preventing its amplification. These results indicate that RNAi silencing does not involve DNA methylation of the *fkba* locus in *M. circinelloides*. Image is representative of two independent experiments.



**Extended Data Figure 3. mRNAs from *fkba* and its neighboring gene *patA* overlap in their 3’ regions by 92 bp**


**a**, The *fkbA* and *patA* genes are convergently oriented. The intergenic region is only 40 bp, and the mRNA overlap of their 3' UTR regions spans 92 nucleotides. **b**, Alignment of the overlapping *fkbA* and *patA* 3' regions based on 3' RACE analysis. The direction of the transcripts are the same as in the upper figure, where the *patA* transcript is 5' to 3' end (top sequence) and the *fkbA* transcript is in the opposite orientation (3' to 5', bottom sequence). The polyA tails of both mRNA are shown.



**Extended Data Figure 4. *patA* expression to generate overlapping RNA molecules is not necessary for *fkbA* silencing**


**a**, Two independent *patA* null mutants (M1=MU434 and M2=MU435) were generated by homologous recombination, employing *pyrG* as the selectable marker. The *patA* ORF was replaced with the *pyrG* gene after electroporation of protoplasts with a gene deletion cassette, generated by overlap PCR, containing the selectable marker *pyrG* flanked by 5' upstream and 3' downstream sequences flanking the *patA* ORF. Almost 400 bp from the 3'

end of *patA* were preserved to keep intact the 3'UTR of *fkba*. PCRs from 5' and 3' junctions (P1/P3 and P4/P2 respectively), the *patA* ORF (P5/P6), and spanning the *patA* and *fkba* loci (P1/P2) were performed to confirm the deletion of the *patA* ORF and correct insertion of the *pyrG* disruption cassette (bottom). Image is representative of two independent experiments. 3'RACE assays were performed to verify that the *pyrG* 3'UTR and *fkba* 3'UTR do not overlap in the *patA* null mutants (See Supplementary Table 2). **b**, Confirmation of the presence of sRNAs in epimutants derived from two independent *patA* null mutants. The numbers of the isolates correspond to those in Supplementary Table 1. An antisense-specific probe was used to detect *fkba* sRNAs by northern blot. 5S rRNA served as a loading control. Abundant sRNAs complementary to *fkba* were detected in all of the FK506<sup>R</sup> strains that lacked Mendelian mutations isolated from the two independent *patA* . sRNA blots were generated once because a positive signal indicates the presence of sRNA.




**Extended Data Figure 5. *fkba* antisense RNA is complementary to mature *fkba* RNA**

The complete sequence of the antisense RNA was determined based on 5' and 3' RACE analyses (bottom sequence) and compared to the *fkba* DNA (top sequence). These analyses indicate the antisense RNA is 5' capped and 3' poly-adenylated. The *fkba* introns were absent in the antisense sequence and the 3' end matched the beginning of the 5' UTR found on *fkba* mRNA by 5' RACE analysis, indicating that mature spliced *fkba* RNA is used as a template by an RdRP to generate the complementary strand. The antisense RNA 5' end is located 7 nt upstream of the STOP codon. The 3' end is located 40 nt upstream of the ATG codon. The *fkba* DNA sequence includes the sequenced 5' and 3' UTR regions in blue and the introns in black. The *fkba* coding region is indicated in red. The ATG start and TAA stop codons are shown in green boxes.



**Extended Data Figure 6. Very few sRNAs were detected by high-throughput sequencing in the WT strain**

The normalized number of reads of each antisense sRNA complementary to *fkbA* is extremely low in the WT strain, and below the detection limit of northern blot (numbers expressed in reads per million). Almost all of the antisense sRNA detected have a uridine at the 5' terminus, features typically found in sRNA that interact with Argonaute proteins, suggesting that they may represent authentic sRNAs but are present at insufficient levels to trigger RNAi silencing. Sense sRNA does not show any bias (data not shown). The height of a letter represents the frequency with which the base is observed in that position, and the total height of the letters in a position indicates how strong the bias is for specific bases in that position. Note that because the total number of *fkbA* antisense reads in the WT strain is very small, they are not probably representative of the true distribution of sRNAs, so the logos are likely to overestimate any sRNA sequence bias.





**b**

Strain	Background	Total analyzed	Mutations in <i>fkba</i>	Mutations in <i>cnaA/cnbR</i>	No mutation found	Epimutants #	Epimutants %	p-value
NRRL3631	WT	33	22	0	11	10	30.3	
EM1-S	NRRL3631 (WT)	24	20	1	3	3	12.5	0.2
EM2-S	NRRL3631 (WT)	23	19	2	2	2	8.7	0.096
EM3-S	NRRL3631 (WT)	22	16	0	6	6	27.3	0.773

**Extended Data Figure 7. Reverted strains (EM1-S, EM2-S, and EM3-S) exposed to a second round of FK506 selection undergo epimutations at the same frequency as the WT strain**  
Epimutant strains (EM1, EM2, and EM3) that had reverted to an FK506 sensitive WT phenotype (yeast growth in the presence of FK506) after several passages on drug-free media were exposed a second time to 1  $\mu$ g/mL FK506 to ascertain if genomic mutations had occurred that enhance epimutant formation. **a**, The numbers of the isolates correspond to those in Supplementary Table 1. The new FK506<sup>R</sup> isolates that lacked a Mendelian mutation in any of the target genes showed abundant sRNAs complementary to *fkba* based on northern blot of sRNA hybridized with an *fkba* antisense-specific probe. 5S rRNA served as a loading control. Images are representative of two independent experiments. EM1-S, EM2-




S, EM3-S =Epimutants 1, 2, and 3 reverted to restored FK506-sensitivity. C+=EM1 before reversion of FK506-resistance. **b**, The frequency of epimutation was similar or lower in the reverted epimutant strains compared to the WT, which argues against mutations that arose promoting epimutation. In addition, because *rdrp1* mutations enhance epimutation frequency and stability, the *rdrp1* gene was sequenced in EM3 and found to be WT with no mutations. *p*-values were obtained based on a Fisher Exact Probability Test for a 2x2 Contingency Table, comparing each of the mutant strains individually versus the WT strain NRRL3631.



**Extended Data Figure 8.** sRNA were detected by high-throughput sequencing in the epimutant strains, but not in the WT and reverted strains. This pattern was not conserved in any other loci in the genome

**a**, sRNAs were found to span exon-exon junctions. Antisense and sense sRNA from EM1 that span intron 1 are shown at the top and bottom respectively. The numbers on the left are the normalized read counts (reads per million) for each specific sRNA. Only sRNAs with 5 or more read counts are shown. The reference sequence is in red and sRNAs spanning the intron are in black. **b**, Distribution of antisense sRNA for the *fkbA* gene across the different strains and the 50 genes with sRNA patterns most closely correlated with *fkbA*. sRNA read counts distribution for the *fkbA* gene is represented with a heavy gray line (left panel). The 50 genes with the closest correlated pattern are represented with thin colored lines. The bottom part of the left panel has been expanded to elucidate the read count patterns of the correlated genes (right panel). While some of these genes show an apparent similarity to the pattern of sRNA in the *fkbA* silenced and revertant strains, the levels of read counts are in most cases ~100-fold lower than that for *fkbA* gene, and were not detected by sRNA blots (data not shown). WT=strain NRRL3631. EM1-R, EM2-R, EM3-R=Epimutants 1, 2, and 3 resistant to FK506. EM1-S and EM3-S=Epimutants 1 and 3 reverted to restored FK506-sensitivity.



**Extended Data Figure 9. sRNA and antisense *fkbA* RNA detection in the different mutant strains lacking RNAi pathway components**

**a**, The numbers of the isolates correspond to those in Supplementary Table 1. No epimutants (absence of sRNA complementary to *fkbA*) were found in the *dcl2* (MU410), *dcl1* (MU407), *ago1* (MU413, MU426), or *rdp2* (MU420, MU428) null mutants based on sRNA northern blots hybridized with an *fkbA* antisense-specific probe. Only one epimutant was recovered in the second independent *dcl1* mutant (MU406). We reconfirmed this result (sRNA blot, no *fkbA* mutation) and also validated the isolate was *dcl1* by PCR. *ago2* (MU416) and *ago3* (MU414) null mutants showed a frequency of epimutation similar to the WT strain (R7B). The *rdp1* null mutant (MU419) showed an elevated epimutation frequency. The conclusion that Dcl2, Dcl1, Ago1, and RdRP2 are required for epimutation is supported by the


congruence of phenotype, and the analysis of two independent null mutants each for *ago1*, *rdrp2*, and *dcl1*. R7B served as WT for this experiment as all of the RNAi silencing mutants were generated in this background. 5S rRNA served as a loading control. C+=EM1 strain. Images from *dicer* mutant blots are representative of two independent experiments. The remaining blots were generated once. **b**, Total RNA was isolated from the WT, *fkbA* mutant, *patA* mutant, R7B and the indicated RNAi pathway mutants, and 50 µg of total RNA were used to ensure signals could be detected from all of the mRNA analyzed, as the level of *patA* expression is low. All of the silencing mutant strains have the same level of expression of the *fkbA* antisense RNA based on northern blot. Antisense- and sense-specific probes were used to detect antisense and sense *fkbA* RNA respectively. The northern blot was first probed for antisense RNA to avoid residual signal from *fkbA* mRNA. *patA* expression was not affected in any the *fkbA* or the RNAi mutant strains, but as expected was absent in the two independent *patA* strains. *actin* served as a loading control. Images are representative of three independent experiments.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Extended Data Figure 10.** *M. circinelloides f. circinelloides* (*Mcc*), and *M. circinelloides f. griseocyanus* (*Mcg*) strains were tested for generation of FK506<sup>R</sup> and *fkbA* silencing

**a**, The indicated *Mucor* strains, plus *M. circinelloides f. lusitanicus* (*Mcl*) WT strain used as a control, were incubated on YPD media for 3 days (top panel) and on YPD supplemented with 1  $\mu\text{g}/\text{mL}$  of FK506 for up to 10 days (lower panels). The *Mcl* and 1006PhL strains grew as a yeast colony until FK506<sup>R</sup> sectors started to grow as hyphae. The *Mucho* strain grew as a yeast colony for several days, and in some of the plates a resistant patch appeared, but after 7-8 days the colonies developed aerial hyphae on top of the yeast colony, producing FK506 sensitive spores that grew as yeast after falling on the media, preventing the development of more FK506<sup>R</sup> patches. The *Mcg* strain was more sensitive to FK506 without a visible colony until day 6 when the spores started to germinate as a mixture of yeast and hyphae that did not produce any FK506<sup>R</sup> growth. Images are representative of ~40 independent colonies from each strain. **b**, Confirmation of the presence of sRNAs in epimutants derived from one of the two pathogenic *M. circinelloides f. circinelloides* strains. The numbers of

the isolates correspond to those in Supplementary Table 5. An antisense strain-specific probe was used to detect *fkba* sRNAs by northern blot from both strains (using 30 µg of sRNA). 5S rRNA served as a loading control. Abundant sRNAs complementary to *fkba* were detected in all of the FK506<sup>R</sup> strains that lacked Mendelian mutations isolated from the 1006PhL strain, but not from the Mucho strain. Images from the lower blots are representative of two independent experiments. Images from the upper blots were generated once since sRNA positive signals were detected from all samples analyzed.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank Rebecca Skalsky and Vikram Ponnusamy for technical support and Johannes Wöstemeyer for trisporic acid. We thank Bryan Cullen, Tom Petes, Blake Billmyre, Marianna Feretzaki, Joanne Kingsbury, and Vikram Ponnusamy for critical reading. This work was supported by NIH grants R37 AI39115-17, R01 AI50438-10, R01 CA154499-04, and the Spanish MICINN BFU2009-07220 and MINECO BFU2012-32246, co-financed by FEDER.


## References

1. Liu J, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell*. 1991; 66:807–815. [PubMed: 1715244]
2. Lee SC, Li A, Calo S, Heitman J. Calcineurin plays key roles in the dimorphic transition and virulence of the human pathogenic zygomycete *Mucor circinelloides*. *PLOS Pathog*. 2013; 9:e1003625. [PubMed: 24039585]
3. Orłowski M. *Mucor* dimorphism. *Microbiol Rev*. 1991; 55:234–258. [PubMed: 1886520]
4. Bastidas RJ, Shertz CA, Lee SC, Heitman J, Cardenas ME. Rapamycin exerts antifungal activity in vitro and in vivo against *Mucor circinelloides* via FKBP12-dependent inhibition of Tor. *Eukaryotic Cell*. 2012; 11:270–281. [PubMed: 22210828]
5. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. *Science*. 1991; 253:905–909. [PubMed: 1715094]
6. Nicolas FE, Torres-Martinez S, Ruiz-Vazquez RM. Two classes of small antisense RNAs in fungal RNA silencing triggered by non-integrative transgenes. *EMBO J*. 2003; 22:3983–3991. [PubMed: 12881432]
7. Nicolas FE, et al. Endogenous short RNAs generated by Dicer 2 and RNA-dependent RNA polymerase 1 regulate mRNAs in the basal fungus *Mucor circinelloides*. *Nucleic Acids Res*. 2010; 38:5535–5541. [PubMed: 20427422]
8. Rhounim L, Rossignol JL, Faugeron G. Epimutation of repeated genes in *Ascobolus immersus*. *EMBO J*. 1992; 11:4451–4457. [PubMed: 1425580]
9. Colot V, Maloisel L, Rossignol JL. Interchromosomal transfer of epigenetic states in *Ascobolus*: transfer of DNA methylation is mechanistically related to homologous recombination. *Cell*. 1996; 86:855–864. [PubMed: 8808621]
10. Cubas P, Vincent C, Coen E. An epigenetic mutation responsible for natural variation in floral symmetry. *Nature*. 1999; 401:157–161. [PubMed: 10490023]
11. Suter CM, Martin DIK, Ward RL. Germline epimutation of *MLH1* in individuals with multiple cancers. *Nature Genetics*. 2004; 36:497–501. [PubMed: 15064764]
12. Chan TL, et al. Heritable germline epimutation of *MSH2* in a family with hereditary nonpolyposis colorectal cancer. *Nature Genetics*. 2006; 38:1178–1183. [PubMed: 16951683]
13. Hitchins MP, et al. Inheritance of a cancer-associated *MLH1* germ-line epimutation. *N Engl J Med*. 2007; 356:697–705. [PubMed: 17301300]

14. Baulcombe DC. RNA as a target and an initiator of post-transcriptional gene silencing in transgenic plants. *Plant Mol Biol.* 1996; 32:79–88. [PubMed: 8980475]
15. Wassenegger M, Pelissier T. A model for RNA-mediated gene silencing in higher plants. *Plant Mol Biol.* 1998; 37:349–362. [PubMed: 9617806]
16. Elmayan T, Vaucheret H. Expression of single copies of a strongly expressed 35S transgene can be silenced post-transcriptionally. *Plant J.* 1996; 9:787–797.
17. Gazzani S, Lawrenson T, Woodward C, Headon D, Sablowski R. A link between mRNA turnover and RNA interference in *Arabidopsis*. *Science.* 2004; 306:1046–1048. [PubMed: 15528448]
18. Calo S, Nicolas FE, Vila A, Torres-Martinez S, Ruiz-Vazquez RM. Two distinct RNA-dependent RNA polymerases are required for initiation and amplification of RNA silencing in the basal fungus *Mucor circinelloides*. *Mol Microbiol.* 2012; 83:379–394. [PubMed: 22141923]
19. de Haro JP, et al. A single dicer gene is required for efficient gene silencing associated with two classes of small antisense RNAs in *Mucor circinelloides*. *Eukaryotic Cell.* 2009; 8:1486–1497. [PubMed: 19666782]
20. Cervantes M, et al. A single *argonaute* gene participates in exogenous and endogenous RNAi and controls cellular functions in the basal fungus *Mucor circinelloides*. *PLOS One.* 2013; 8:e69283. [PubMed: 23935973]
21. Nicolas FE, de Haro JP, Torres-Martinez S, Ruiz-Vazquez RM. Mutants defective in a *Mucor circinelloides* dicer-like gene are not compromised in siRNA silencing but display developmental defects. *Fungal Genet Biol.* 2007; 44:504–516. [PubMed: 17074518]
22. Kennedy S, Wang D, Ruvkun G. A conserved siRNA-degrading RNase negatively regulates RNA interference in *C. elegans*. *Nature.* 2004; 427:645–649. [PubMed: 14961122]
23. Timmons L. Endogenous inhibitors of RNA interference in *Caenorhabditis elegans*. *BioEssays.* 2004; 26:715–718. [PubMed: 15221853]
24. Gent JI, et al. Distinct phases of siRNA synthesis in an endogenous RNAi pathway in *C. elegans* soma. *Mol Cell.* 2010; 37:679–689. [PubMed: 20116306]
25. Reyes-Turcu FE, Grewal SI. Different means, same end-heterochromatin formation by RNAi and RNAi-independent RNA processing factors in fission yeast. *Curr Opin Genet Dev.* 2012; 22:156–163. [PubMed: 22243696]
26. Yamanaka S, et al. RNAi triggered by specialized machinery silences developmental genes and retrotransposons. *Nature.* 2013; 493:557–560. [PubMed: 23151475]
27. Li CH, et al. Sporangiospore size dimorphism is linked to virulence of *Mucor circinelloides*. *PLoS Pathog.* 2011; 7:e1002086. [PubMed: 21698218]
28. Lee SC, et al. Analysis of a foodborne fungal pathogen outbreak: virulence and genome of a *Mucor circinelloides* isolate from yogurt. *mBio.* 2014 in press.
29. Lasker BA, Borgia PT. High-frequency heterokaryon formation by *Mucor racemosus*. *J Bacteriol.* 1980; 141:565–569. [PubMed: 7364713]
30. Wetzel J, Burmester A, Kolbe M, Wostemeyer J. The mating-related loci *sexM* and *sexP* of the zygomycetous fungus *Mucor mucedo* and their transcriptional regulation by trisporoid pheromones. *Microbiology.* 2012; 158:1016–1023.10.1099/mic.0.054106-0 [PubMed: 22262094]
31. Murcia-Flores L, Lorca-Pascual JM, Garre V, Torres-Martinez S, Ruiz-Vazquez RM. Non-AUG translation initiation of a fungal RING finger repressor involved in photocarotenogenesis. *J Biol Chem.* 2007; 282:15394–15403. [PubMed: 17403679]
32. Cardenas ME, Heitman J. FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity. *EMBO J.* 1995; 14:5892–5907. [PubMed: 8846782]
33. Gutierrez A, Lopez-Garcia S, Garre V. High reliability transformation of the basal fungus *Mucor circinelloides* by electroporation. *J Microbiol Methods.* 2011; 84:442–446. [PubMed: 21256886]
34. Grigoriev IV, et al. The genome portal of the Department of Energy Joint Genome Institute. *Nucleic Acids Res.* 2012; 40:D26–32. [PubMed: 22110030]
35. Kim D, et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol.* 2013; 14:R36. [PubMed: 23618408]


36. Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: a sequence logo generator. *Genome Res.* 2004; 14:1188–1190. [PubMed: 15173120]
37. Heger, A. pysam: Python interface for the SAM/BAM sequence alignment and mapping format. 2013. <http://code.google.com/p/pysam/>
38. Anders S, Huber W. Differential expression analysis for sequence count data. *Genome Biol.* 2010; 11:R106. [PubMed: 20979621]
39. Cock PJ, et al. Biopython: freely available Python tools for computational molecular biology and bioinformatics. *Bioinformatics.* 2009; 25:1422–1423. [PubMed: 19304878]
40. Hunter JD. Matplotlib: A 2D graphics environment. *Comput Sci Eng.* 2007; 9:90–95.
41. Oliphant TE. Python for scientific computing. *Comput Sci Eng.* 2007; 9:10–20.
42. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res.* 2002; 30:207–210. [PubMed: 11752295]
43. Anders S, Pyl PT, Huber W. HTSeq - A Python framework to work with high-throughput sequencing data. *bioRxiv.* 2014
44. R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2013.





**Figure 1. RNAi-dependent epimutations confer FK506-resistance in *M. circinelloides***

**a**, WT, *fkbA* mutant (*fkbAΔ*), and epimutant strains were grown on YPD media alone or supplemented with FK506, rapamycin, or cyclosporin A (CsA). Images representative of several independent experiments. **b-c**, The epimutant strains EM1, EM2, and EM3 were grown on YPD media with FK506 (FK506 lanes), or YPD drug-free media (R lanes). The reverted strains EM1-S, EM2-S, and EM3-S (S lanes) were grown in YPD media and whole cell protein and RNA extracts were prepared. **b**, Equivalent protein amounts (120  $\mu$ g) were resolved by SDS-PAGE and analyzed by western blot with an anti-*S. cerevisiae*-FKBP12 antibody. An *S. cerevisiae* extract (Sc) was included as control for antibody specificity; tubulin served as loading control. Images representative of seven independent experiments. **c**, 50  $\mu$ g total mRNA was analyzed by northern blot employing probes specific for *fkbA*, *act1* (loading control), and antisense *fkbA* mRNAs. Images representative of six independent experiments for the *fkbA* and *act1* probes, and two for the antisense *fkbA* probe.



**Figure 2. Epimutant strains express abundant sRNA antisense to *fkbA***

**a**, sRNAs were extracted from WT, epimutants (FK506 and R lanes), and reverted strains (S lanes) after growth in YPD media alone (R, S lanes) or with FK506 (FK506 lanes). sRNAs (25 $\mu$ g) were analyzed by sRNA blot employing an antisense-specific probe for the *fkbA* gene or a probe for 5S *rRNA* (loading control). Images representative of three independent experiments. **b**, The presence of sense and antisense *fkbA* sRNA was analyzed by high-throughput sequencing in WT, epimutants, and two revertant strains (EM1-S, EM3-S). sRNA amount is expressed in reads per million, and they are distributed along the *fkbA* ORF (bottom) **c**, Analysis of size and first nucleotide (inset) of antisense sRNAs. The representation corresponds to data obtained from isolate EM1-R. Similar results were observed for the EM2-R and EM3-R epimutants.

**Table 1**

Frequency of epimutants/mutants in the WT, *patA*, and RNAi mutant strains.

Strain	Background	Total analyzed	Mutations in <i>flbA</i>	Mutations in <i>enaA/cnbR</i>	No mutation found	Epimutants #	Epimutants %	<i>p</i> -value*
NRRL3631	Wild type	33	22	0	11	10	30.3	
R7B	<i>leuA</i> -	31	22	1	8	7	22.6	
MU434	<i>patA</i> : : <i>pyrGleuA</i> -	33	28	0	5	5	15.2	0.531
MU435	<i>patA</i> : : <i>pyrGleuA</i> -	33	26	0	7	7	21.2	1
MU406	<i>dcil</i> : : <i>pyrGleuA</i> -	25	23	1	1	1	4	0.06
MU407	<i>dcil</i> : : <i>pyrGleuA</i> -	21	18	3	0	0	<4.8	0.033
MU410	<i>dcI2</i> : : <i>pyrGleuA</i> -	34	31	2	1	0	<2.9	0.004
MU413	<i>ago1</i> : : <i>pyrGleuA</i> -	26	25	1	0	0	<3.8	0.012
MU426	<i>ago1</i> : : <i>pyrGleuA</i> -	27	27	0	0	0	<3.7	0.012
MU416	<i>ago2</i> : : <i>pyrGleuA</i> -	23	16	3	4	4	17.4	0.741
MU414	<i>ago3</i> : : <i>pyrGleuA</i> -	27	22	1	4	4	14.8	0.518
MU419	<i>rdp1</i> : : <i>pyrGleuA</i> -	32	6	0	26	26	81.3	0.000004
MU420	<i>rdp2</i> : : <i>pyrGleuA</i> -	25	23	2	0	0	<4.0	0.013
MU428	<i>rdp2</i> : : <i>pyrGleuA</i> -	27	26	1	0	0	<3.7	0.012

\* *p*-values were obtained based on a Fisher Exact Probability Test for a 2x2 Contingency Table, comparing each of the mutant strains individually versus the R7B strain.